Episodios

  • Lessons Learned in the Development and Introduction of Closed Loop Systems

    Lessons Learned in the Development and Introduction of Closed Loop Systems
    May 21 2025
    This podcast features a panel discussion from the 2024 PODD Conference with pharma, medtech and academic leaders about technological development and patient and clinical adoption of closed-loop systems. Specifically:
    • Success in diabetes and lessons for other indications like oncology and CNS
    • New frontiers in improving closed-loop therapies
    • Increasing access across therapy areas
    To learn more about the PODD conference, please visit Drug-Delivery.org.
    Más Menos
    32 m
  • Best Practices and Potential Pitfalls Enriching Clinical Trials with PROs

    Best Practices and Potential Pitfalls Enriching Clinical Trials with PROs
    May 21 2025
    Patient-reported outcomes (PROs) are increasingly recognized by regulators, clinicians, and patients as valuable tools to collect patient-centered data. This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with biotech CMOs about how to incorporate PROs into clinical trials in ways that improve probabilities of success while avoiding common mistakes. Specifically, the panelists address:
    • How PROs provide evidence on the effect of interventions on patient symptoms and quality of life, but by the nature of being subjective, they are prone to bias
    • The growth of electronic health technologies provides unprecedented opportunities to systematically collect PROs
    • Disadvantages of electronic methods include technical difficulties, cost, longer start-up time, and “digital divide” between patients
    To learn more about the PODD conference, please visit CMO360.org.
    Más Menos
    33 m
  • Operationalizing the Patient Voice for Long-Term Protocol Planning and Execution

    Operationalizing the Patient Voice for Long-Term Protocol Planning and Execution
    May 19 2025
    Summary:
    This podcast from the 2024 DPHARM conference showcases the value of patient engagement as a core strategic investment by focusing on the connection between patient engagement and tangible patient benefits / long-term business sustainability.

    The case example from Roche uses patient burden and protocol complexity in late-stage clinical development to demonstrate how this connection can be done in larger corporations and to emphasize patient engagement as a long-term growth driver and not just a short-term cost.
    More specifically:


    • Protocol design and executional practice, and the impact of current practices on protocol performance
    • Framework, process and use cases for optimization of protocol performance through operationalization of patient preferences
    • Direct impact on corporate goals like recruitment, retention and growth
    For more information, go to DPHARMconference.com
    Más Menos
    30 m
  • Navigating Data Quality and Scalability Challenges when Using Real-World Data from EHRs

    Navigating Data Quality and Scalability Challenges when Using Real-World Data from EHRs
    May 14 2025
    Summary:
    In this podcast from the 2024 CRAACO: Clinical Research as a Care Option conference, Dr Meredith Zozus, UT Health San Antonio, walks through several studies illustrating differences in data quality and scalability using EHRs in the conduct of structured protoocls versus retrospective studies using EHR. The results highlight the important methods and approaches for using EHR data in clinicla studies, which is a key component of integrating care and research.

    For more information, go to CRAACOevent.com.
    Más Menos
    27 m
  • Addressing the Realities of Scaling T-Cell Therapies for Patient Access and Affordability

    Addressing the Realities of Scaling T-Cell Therapies for Patient Access and Affordability
    May 14 2025
    Summary:
    This podcast delves into the critical challenges of scalability in T-cell therapies (including CAR-T, TILs, and TCR-T). The panelists discuss the primary obstacles hindering the increased availability of T-cell therapies to patients, the most promising upcoming approaches to enhance access, the greatest opportunities to improve efficiencies and scalability, and the developments in the near future that could help meet growing demand.

    For more information, go to IO360summit.com.
    Más Menos
    40 m
  • The Current Status of Patient Centricity in Medicine Development

    The Current Status of Patient Centricity in Medicine Development
    May 14 2025
    Summary:
    This podcast focuses on the current state of patient centricity within the biopharmaceutical industry, how it's being implemented, operationalized and scaled within organizations, and showing the tangible value of engaging patients.

    Dr Matthew Reney, Scientific Lead, Patient-Centered endpoints at IQVIA, speaks with Dr Anthony Yanni, SVP, Head of Patient Centricity at Astellas, to share their experiences, what they've seen in patient centricity gains, standing up patient centricity functions and proving the business case for doing so.

    For more information, go to theconferenceforum.org.
    Más Menos
    26 m
  • Patients as Partners Caregiver Keynote - The Life-Changing Power of a Clinical Trial

    Patients as Partners Caregiver Keynote - The Life-Changing Power of a Clinical Trial
    Apr 28 2025
    Summary:
    In this podcast, recorded at the 2025 Patients as Partners in Clinical Research conference, patient advocate and caregiver Dr Justin Hopkin, University of Rochester, describes his family's journey before, during and after his son was diagnosed with a rare, life-threatening disease.

    Dr Hopkin talks about the process of getting a diagnosis, the critical role of a clinical trial for his son, the impact on his other children, and his advice for medicine developers and clinical trial designers.

    For more information, go to PatientsAsPartnersConference.com
    Más Menos
    24 m
  • Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape

    Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape
    Apr 23 2025
    Summary:
    This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.

    More specifically:
    • Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting both PD-1 and VEGF
    • Insights into how these developments could influence industry trends and investor sentiment
    • Forward-looking forecasts on market share and commercial positioning for PD-1/PD-L1 and VEGF-targeting therapies






    In this podcast:
    • Roy Baynes, MD, PhD, EVP & CMO at Eikon Therapeutics





    • Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst at Truist Securities

    For more information, go to IO360summit.com
    Más Menos
    20 m
adbl_web_global_use_to_activate_T1_webcro805_stickypopup